[1]Patent:WO2013/14448,2013,A1,.Locationinpatent:Page/Pagecolumn65;66
[2]Patent:CN106674202,2017,A,.Locationinpatent:Paragraph0072
[3]Patent:CN107043369,2017,A,.Locationinpatent:Paragraph0527;0528;0529;0530;0531;0532
[4]Patent:CN108929311,2018,A,.Locationinpatent:Paragraph0244-0247
[5]Patent:CN108623567,2018,A,.Locationinpatent:Paragraph0068;0069;0070
[6]Patent:CN107522690,2017,A,.Locationinpatent:Paragraph0030;0031;0035;0036;0040;0041;0045;0046
[7]Patent:CN108218839,2018,A,.Locationinpatent:Paragraph0031
[1]Patent:CN109134435,2019,A,.Locationinpatent:Paragraph0056-0074
[2]Patent:CN106543060,2017,A,.Locationinpatent:Paragraph0053-0055
[3]Patent:CN108129342,2018,A,.Locationinpatent:Paragraph0057;0058;0059
[4]Patent:CN107216313,2017,A,.Locationinpatent:Paragraph0074;0074
[5]JournalofHeterocyclicChemistry,2017,vol.54,#5,p.2898-2901
[6]Patent:CN106366072,2017,A,.Locationinpatent:Paragraph0079;0080;0081;0082;0111-0115
[7]Patent:CN106366022,2017,A,.Locationinpatent:Paragraph0084;0085;0086;0087;0088;0089;0090
[8]Patent:CN107793413,2018,A,.Locationinpatent:Paragraph0191-0194
[9]EuropeanJournalofMedicinalChemistry,2017,vol.135,p.12-23
[10]Patent:WO2013/14448,2013,A1,.Locationinpatent:Page/Pagecolumn65
[11]JournalofMedicinalChemistry,2014,vol.57,#20,p.8249-8267
[1]Patent:WO2013/14448,2013,A1,.Locationinpatent:Page/Pagecolumn66
[2]Patent:CN106699736,2017,A,.Locationinpatent:Paragraph0045;0046;0047;0048;0049
[3]Patent:CN107188888,2017,A,.Locationinpatent:Paragraph0073-0075
[1]Patent:CN104817541,2017,B,.Locationinpatent:Paragraph0047-0048
[2]JournalofChemicalResearch,2015,vol.39,#6,p.318-320
[3]Patent:CN105601620,2016,A,.Locationinpatent:Paragraph0102;0103;0104;0105;0106;0107;0108-0114
[1]Patent:CN104910049,2016,B,.Locationinpatent:Paragraph0049;0050
[1]Patent:WO2013/14448,2013,A1
[2]Patent:WO2013/14448,2013,A1
[3]Patent:WO2013/14448,2013,A1
[4]JournalofChemicalResearch,2015,vol.39,p.318-320
[5]Patent:CN106366072,2017,A
[6]Patent:CN106366022,2017,A
[7]Patent:CN106543060,2017,A
[8]EuropeanJournalofMedicinalChemistry,2017,vol.135,p.12-23
[9]Patent:CN104817541,2017,B
[10]JournalofHeterocyclicChemistry,2017,vol.54,p.2898-2901
[11]Patent:CN106967050,2017,A
[12]Patent:CN107188888,2017,A
[13]Patent:CN107216313,2017,A
[14]Patent:CN107216313,2017,A
[15]Patent:CN107793413,2018,A
[16]Patent:CN108129342,2018,A
[17]Patent:CN108129342,2018,A
[18]Patent:CN108623567,2018,A
[1]Patent:WO2013/14448,2013,A1
[2]Patent:CN106674202,2017,A
[3]Patent:CN108623567,2018,A
[1]Patent:CN109134435,2019,A.Locationinpatent:Paragraph0056-0074
[2]Patent:CN106543060,2017,A.Locationinpatent:Paragraph0053-0055
[3]Patent:CN108129342,2018,A.Locationinpatent:Paragraph0057;0058;0059
[4]Patent:CN107216313,2017,A.Locationinpatent:Paragraph0074;0074
[5]JournalofHeterocyclicChemistry,2017,vol.54,p.2898-2901
[6]Patent:CN106366072,2017,A.Locationinpatent:Paragraph0079;0080;0081;0082;0111-0115
[7]Patent:CN106366022,2017,A.Locationinpatent:Paragraph0084;0085;0086;0087;0088;0089;0090
[8]Patent:CN107793413,2018,A.Locationinpatent:Paragraph0191-0194
[9]EuropeanJournalofMedicinalChemistry,2017,vol.135,p.12-23
[10]Patent:WO2013/14448,2013,A1.Locationinpatent:Page/Pagecolumn65
[11]JournalofMedicinalChemistry,2014,vol.57,p.8249-8267
[1]Patent:WO2013/14448,2013,A1.Locationinpatent:Page/Pagecolumn66
[2]Patent:CN106699736,2017,A.Locationinpatent:Paragraph0045;0046;0047;0048;0049
[3]Patent:CN110437209,2019,A.Locationinpatent:Paragraph0547-0552
[4]Patent:CN107188888,2017,A.Locationinpatent:Paragraph0073-0075
[1]Patent:WO2013/14448,2013,A1
[2]Patent:WO2013/14448,2013,A1
[3]Patent:WO2013/14448,2013,A1
[4]JournalofMedicinalChemistry,2014,vol.57,p.8249-8267
[5]EuropeanJournalofMedicinalChemistry,2017,vol.135,p.12-23
[6]Patent:CN107188888,2017,A
[7]Patent:CN107216313,2017,A
[8]Patent:CN107793413,2018,A
[9]Patent:CN108623567,2018,A
[10]Patent:CN109134435,2019,A
Title: L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20161001
Title: Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
Journal: Journal of medicinal chemistry 20160728
Title: Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Journal: Therapeutic advances in respiratory disease 20160401
Title: Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20160401
Title: Osimertinib: First Global Approval.
Journal: Drugs 20160201
Title: Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
Journal: Journal of hematology & oncology 20160101
Title: Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.
Journal: Journal of structural biology 20151201
Title: Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.
Journal: JAMA oncology 20151001
Title: Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20150901
Title: Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Journal: The Lancet. Oncology 20150901
Title: The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC).
Journal: Annals of translational medicine 20150501
Title: Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Journal: Current opinion in oncology 20150301
Title: Dacomitinib in lung cancer: a 'lost generation' EGFR tyrosine-kinase inhibitor from a bygone era?
Journal: Drug design, development and therapy 20150101
Title: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Journal: Cancer discovery 20140901
Title: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN 20130201
Title: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Journal: The New England journal of medicine 20040520